- Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)Yamamoto, S.; Lin, C-Y.; Rojas, C.; Herrero, F. Rivera; Kwong, D. L. W.; Chen, M-H.; Zhang, Y.; Yu, L.; Shah, S.; Bhagia, P.; Shen, L.; Sun, J-M.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Penpulimab plus chemotherapy with or without anlotinib as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ANSWER): A randomized, two-arm, clinical trial in progress.Wang, Wei; Lin, Shuimiao; Wang, Rong; Wu, DehuaGenitourinary Cancers Symposium, San Francisco, CA, 2023-01-19 To 2023-01-21.
- First-line serplulimab versus placebo in combination with chemotherapy in PD-L1-positive oesophageal squamous cell carcinoma (ASTRUM-007): A randomised, double-blind, multicentre phase III studyHuang, J.; Song, Y.; Kou, X.; Tan, Z.; Zhang, S.; Sun, M.; Zhou, J.; Fan, M.; Zhang, M.; Song, Y.; Li, S.; Yuan, Y.; Zhuang, W.; Zhang, J.; Zhang, L.; Jiang, H.; Gu, K.; Ye, H.; Wang, Q.; Zhu, J.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.被引 1
会议论文
First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (mESCC): Safety run-in results from the phase III LEAP-014 study
10阅读
